Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Retrieved on:
Tuesday, November 26, 2019
Biotechnology, General Health, Pharmaceutical, Health, Lung cancer, Cancer, Clinical medicine, Treatment of lung cancer, Non-small-cell lung carcinoma, Pembrolizumab, Pemetrexed, Small-cell carcinoma, Anaplastic lymphoma kinase, Atezolizumab, Combined small-cell lung carcinoma, Lung Cancer in China, KEYTRUDA® (pembrolizumab) Injection, Merck
Importantly, KEYTRUDA provides a foundation for the treatment of lung cancer in China and now more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA.
Key Points:
- Importantly, KEYTRUDA provides a foundation for the treatment of lung cancer in China and now more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA.
- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
- KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.